Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2007-02-07
2010-06-22
Weddington, Kevin (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
Reexamination Certificate
active
07741367
ABSTRACT:
The present invention provides compositions and methods for treating and/or preventing diseases and disorders associated with expression of PPAR γ and/or infiltration of macrophages into skeletal muscle tissue and/or white adipose tissue. The method treats such diseases and disorders with abscisic acid (ABA). Exemplary diseases and disorders include diabetes, including type 2 diabetes, prediabetes, glucose intolerance insulin resistance, and diseases and disorders involving the immune system, such as inflammation, including obesity-related inflammation, inflammatory bowel disease, type 1 diabetes, multiple sclerosis, allergies, asthma, cardiovascular disease, and arthritis.
REFERENCES:
patent: 3958025 (1976-05-01), Livingston
patent: 2004/0052922 (2004-03-01), Pistolesi
patent: 2004/0216194 (2004-10-01), Hauptmann et al.
patent: 2005/0260181 (2005-11-01), Girsh
patent: 03169811 (1991-07-01), None
The English abstract of Miyazaki et al. (JP 03169811A) enclosed.
Guri, A.J. et al., “Dietary abscisic acid ameliorates glucose tolerance and obesity-related inflammation in db/db mice fed high-fat diets”,Clinical Nutrition26:107-116, 2007.
Lehrke, M. and M.A. Lazar, “The Many Faces of PPAR γ”,Cell123:993-999, Dec. 16, 2005.
National Diabetes Fact Sheet, 2005, Centers For Disease Control And Prevention, www.cdc.gov/diabetes.
Narayan, L.M.V. et al., “Lifetime Risk for Diabetes Mellitus in the United States”,JAMA290(14):1884-1890, Oct. 8, 2003.
Nesto, R.W. et al., “Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure”,Diabestes Care27(1):256-263, Jan. 2004.
Olefsky, J.M., “Treatment of insulin resistance with peroxisome proliferator-activated receptor γ agonists”,The Journal of Clinical Investigation106(4):467-472, Aug. 2000.
Wysowski, D.K. et al., “Rapid Increase in the Use of Oral Antidiabetic Drugs in the United States, 1990-2001”,Diabetes Care26(6):1852-1855, Jun. 2003.
von Lintig, et al., “Towards a better understanding of carotenoid metabolism in animals,” Biochimica et Biophysica Acta (BBA)- Molecular Basis of Disease May 2005, 1740(2):122-131 ; p. 128, col. 2.
Desvergne et al., “Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolis,” Endocrine Reviews, Oct. 1999, 20(5):649-658, p. 663-664 and p. 667.
Search Report and Written Opinion, PCT/US2007/003366.
Bassaganya-Riera Josep
Guri Amir
Hontecillas Raquel
Blank Rome LLP
Virginia Tech Intellectual Properties Inc.
Weddington Kevin
LandOfFree
Method of using abscisic acid to treat diseases and disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of using abscisic acid to treat diseases and disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of using abscisic acid to treat diseases and disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4218624